Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

NCT03424603 is registered in ClinicalTrials.gov with Sutro Biopharma, Inc. as lead sponsor.

NCT NCT03424603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03424603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Lead sponsor
Sutro Biopharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 22, 2018
Completion date
March 15, 2024
Enrollment
70 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

b cells--tumors, b-cell lymphoma, diffuse large b cell lymphoma, follicular lymphoma, indolent lymphoma, mantle cell lymphoma, multiple myeloma, non hodgkin lymphoma